Meta-analysis of epoetin beta and darbepoetin alfa treatment for chemotherapy-induced anemia and mortality: Individual patient data from Japanese randomized, placebo-controlled trials

Cancer Science

Volumn 104, Issue 4, 2013, Pages 481-485

  Ohashi, Yasuo ^a   Uemura, Yukari ^a   Fujisaka, Yasuhito ^b,g   Sugiyama, Toru ^c   Ohmatsu, Hironobu ^d   Katsumata, Noriyuki ^e,i   Okamoto, Rumiko ^f   Saijo, Nagahiro ^g,j   Hotta, Tomomitsu ^h,k  

^a UNIVERSITY OF TOKYO   (Japan)

^b OSAKA MEDICAL COLLEGE HOSPITAL   (Japan)

^c IWATE MEDICAL UNIVERSITY   (Japan)

^d NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^e NATIONAL CANCER CENTER HOSPITAL   (Japan)

^f TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^g KINKI UNIVERSITY   (Japan)

^h NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

ⁱ NIPPON MEDICAL SCHOOL MUSASHI KOSUGI HOSPITAL   (Japan)

^j Japanese Society of Medical Oncology   (Japan)

^k NATIONAL CANCER CENTER   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ADVERSE OUTCOME; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED ANEMIA; DRUG SAFETY; GYNECOLOGIC CANCER; HEMOGLOBIN BLOOD LEVEL; HUMAN; JAPANESE; LUNG CANCER; LYMPHOMA; META ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; SOLID TUMOR;

ANEMIA; ANTINEOPLASTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; ERYTHROPOIETIN; HEMATINICS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOMBINANT PROTEINS;

EID: 84875624906     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12105     Document Type: Article

References (28)

1. Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B, Epoetin Alfa Study Group. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001; 19: 2865-74.
2. Osterborg A, Brandberg Y, Molostova V et al. Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematologic malignancies. J Clin Oncol 2002; 20: 2486-94.
3. Vansteenkiste J, Pirker R, Massuti B et al. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 2002; 94: 1211-20.
4. Leyland-Jones B. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 2003; 4: 459-60.
5. Henke M, Laszig R, Rübe C et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003; 362: 1255-60.
6. Hedenus M, Adriansson M, San Miguel J et al. Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. Br J Haematol 2003; 122: 394-403.
7. Wright JR, Ung YC, Julian JA et al. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol 2007; 25: 1027-32.
8. Smith RE Jr, Aapro MS, Ludwig H et al. Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. J Clin Oncol 2008; 26: 1040-50.
9. Thomas G, Ali S, Hoebers FJ et al. Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin vs above 10.0 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer. Gynecol Oncol 2008; 108: 317-25.
10. Jeong JY, Feldman L, Solar P, Szenajch J, Sytkowski AJ. Characterization of erythropoietin receptor and erythropoietin expression and function in human ovarian cancer cells. Int J Cancer 2008; 122: 274-80.
11. Jeong JY, Hoxhaj G, Socha AL, Sytkowski AJ, Feldman L. An erythropoietin autocrine/paracrine axis modulates the growth and survival of human prostate cancer cells. Mol Cancer Res 2009; 7: 1150-7.
12. Jelkmann W, Bohlius J, Hallek M, Sytkowski AJ. The erythropoietin receptor in normal and cancer tissues. Crit Rev Oncol Hematol 2008; 67: 39-61.
13. Aapro M, Jelkmann W, Constantinescu SN, Leyland-Jones B. Effects of erythropoietin receptors and erythropoiesis-stimulating agents on disease progression in cancer. Br J Cancer 2012; 106: 1249-58.
14. Bohlius J, Schmidlin K, Brillant C et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet 2009; 373: 1532-42.
15. Glaspy J, Crawford J, Vansteenkiste J et al. Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. Br J Cancer 2010; 102: 301-15.
16. Bennett CL, Silver SM, Djulbegovic B et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008; 299: 914-24.
17. Tonelli M, Hemmelgarn B, Reiman T et al. Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis. CMAJ 2009; 180: E62-71.
18. Ross SD, Allen IE, Henry DH, Seaman C, Sercus B, Goodnough LT. Clinical benefits and risks associated with epoetin and darbepoetin in patients with chemotherapy-induced anemia: a systematic review of the literature. Clin Ther 2006; 28: 801-31.
19. Seidenfeld J, Piper M, Bohlius J et al. Comparative effectiveness of epoetin and darbepoetin for managing anemia in patients undergoing cancer treatment. Agency for Healthcare Research and Quality Comparative Effectiveness Reviews No.3; 2006 May.
20. Katakami N, Nishiwaki Y, Fujiwara Y et al. Randomized, double-blind, placebo-controlled phase III study of weekly administration of darbepoetin alfa (DA) in anemic patients with lung or gynecologic cancer receiving platinum-containing chemotherapy. Ann Oncol 2008; 19 (Suppl. 8): 277-8.
21. Suzuki Y, Tokuda Y, Okamoto R et al. Randomized, placebo-controlled phase II study of darbepoetin alfa (DA) administered every three weeks (Q3W) in patients with chemotherapy-induced anemia (CIA). Ann Oncol 2008; 19 (Suppl. 8): 277.
22. Fujisaka Y, Sugiyama T, Saito H et al. Randomized, phase III trial of epoetin beta to treat chemotherapy-induced anemia according to the EU Regulation. Br J Cancer 2011; 105: 1267-72.
23. Kunikane H, Watanabe K, Fukuoka M et al. Double-blind randomized control trial of the effect of recombinant human erythropoietin on chemotherapy-induced anemia in patients with non-small cell lung cancer. Int J Clin Oncol 2001; 6: 296-301.
24. Tsuboi M, Ezaki K, Tobinai K, Ohashi Y, Saijo N. Weekly administration of epoetin beta for chemotherapy-induced anemia in cancer patients: results of a multicenter, phase III, randomized, double-blind, placebo-controlled study. Jpn J Clin Oncol 2009; 39: 163-8.
25. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. New York: John Wiley & Sons, 1980.
26. Aihara T, Takatsuka Y, Ohsumi S et al. Phase III randomized adjuvant study of tamoxifen alone versus sequential tamoxifen and anastrozole in Japanese postmenopausal women with hormone-responsive breast cancer: N-SAS BC03 study. Breast Cancer Res Treat 2010; 121: 379-87.
27. Morishima Y, Ogura M, Yoneda S et al. Once-weekly epoetin-beta improves hemoglobin levels in cancer patients with chemotherapy-induced anemia: a randomized, double-blind, dose-finding study. Jpn J Cin Oncol 2006; 36: 655-61.
28. Suzuki Y, Tokuda Y, Fujiwara Y, Minami H, Ohashi Y, Saijo N. Weekly epoetin beta maintains hemoglobin levels and improves quality of life in patients with non-myeloid malignancies receiving chemotherapy. Jpn J Cin Oncol 2008; 38: 214-21.